Comments on the theory, methods, and potential of the sepsis-detecting Cytovale System from Cytovale CEO and co-founder, Ajay Shah, Ph.D.
Preliminary data from a phase 1/2 trial indicate that Principia Biopharma’s BTK inhibitor Rilzabrutinib could treat immune thrombocytopenia.
Australian researchers found that T cells engineered to express the dendritic cell growth factor Flt3L overcame an important obstacle to the treatment of solid tumors.
Swiss scientists have found that the function of follicular dendritic cells within germinal centers is influenced by their spatial position.
Portuguese researchers discovered that type 1 regulatory T cells increase the availability of TGF-beta to promote CD8+ TRM T cell generation.
Celldex Therapeutics’ CDX-0159, an inhibitor of the KIT receptor, led to sustained reductions in plasma tryptase levels in the phase 1 trial.
The team of Dr. Katerina Akassoglou at Gladstone Institutes and UCSF studied the gene signature of pathogenic innate immune cells in the CNS.
Calquence (Acalabrutinib), Astrazeneca’s bruton tyrosine kinase inhibitor, is thought to treat COVID-19 by suppressing lung macrophages.
Gilead and Galapagos NV announced the results of two phase 2 human trials evaluating filgotinib in adults with psoriatic arthritis.
Rights to the antibody candidate JTX-8064 have been transferred from Bristol-Myers Squibb back to Jounce Therapeutics effective June 3rd 2020.